Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$26.4
Market cap
$15.55B
P/E Ratio
10.27
Dividend/share
$0.84
EPS
$2.57
Enterprise value
$22.21B
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals
Highlights
The P/E is 79% lower than the 5-year quarterly average of 48.4 and 27% lower than the last 4 quarters average of 14.1
The net income has soared by 70% from the previous quarter
The company's quick ratio has shrunk by 89% YoY and by 84% QoQ
Royalty Pharma's debt has increased by 24% YoY
Key stats
What are the main financial stats of RPRX
Market
Valuations
Earnings
Shares outstanding
589.18M
Market cap
$15.55B
Enterprise value
$22.21B
Price to earnings (P/E)
10.27
Price to book (P/B)
1.53
Price to sales (P/S)
5.22
EV/EBIT
16.43
EV/EBITDA
16.43
EV/Sales
9.8
Revenue
$2.27B
EBIT
$1.35B
EBITDA
$1.35B
Free cash flow
$2.75B
Per share
Balance sheet
Liquidity
EPS
$2.57
Free cash flow per share
$6.14
Book value per share
$17.29
Revenue per share
$5.06
TBVPS
$40.31
Total assets
$18.04B
Total liabilities
$7.78B
Debt
$7.61B
Equity
$10.26B
Working capital
$626.44M
Debt to equity
0.74
Current ratio
1.54
Quick ratio
1.53
Net debt/EBITDA
4.92
Margins
Efficiency
Dividend
EBITDA margin
59.7%
Gross margin
100%
Net margin
50.5%
Operating margin
68.1%
Return on assets
6.7%
Return on equity
11.5%
Return on invested capital
6%
Return on capital employed
8%
Return on sales
59.7%
Dividend yield
3.18%
DPS
$0.84
Payout ratio
32.7%
RPRX stock price
How has the Royalty Pharma stock price performed over time
Intraday
0.69%
1 week
3.21%
1 month
-4.86%
1 year
-2.22%
YTD
-6.02%
QTD
-6.68%
Financial performance
How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.27B
Gross profit
$2.27B
Operating income
$1.54B
Net income
$1.15B
Gross margin
100%
Net margin
50.5%
The net income has soared by 70% from the previous quarter
Royalty Pharma's net margin has surged by 68% QoQ
The operating income has soared by 61% from the previous quarter
The operating margin has surged by 59% since the previous quarter
Growth
What is Royalty Pharma's growth rate over time
Valuation
What is Royalty Pharma stock price valuation
P/E
10.27
P/B
1.53
P/S
5.22
EV/EBIT
16.43
EV/EBITDA
16.43
EV/Sales
9.8
The P/E is 79% lower than the 5-year quarterly average of 48.4 and 27% lower than the last 4 quarters average of 14.1
Royalty Pharma's EPS has surged by 70% QoQ
RPRX's P/B is 41% below its 5-year quarterly average of 2.6 and 10% below its last 4 quarters average of 1.7
RPRX's equity is up by 7% year-on-year and by 5% since the previous quarter
The P/S is 25% below the 5-year quarterly average of 7.0 and 7% below the last 4 quarters average of 5.6
The revenue has decreased by 2.5% YoY
Efficiency
How efficient is Royalty Pharma business performance
RPRX's ROE has soared by 67% from the previous quarter
The ROA has soared by 63% from the previous quarter
Royalty Pharma's return on sales has surged by 55% QoQ
The ROIC has soared by 54% QoQ
Dividends
What is RPRX's dividend history
DPS
$0.84
Dividend yield
3.18%
Payout ratio
32.7%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 132% more than its total liabilities
The current ratio has dropped by 89% year-on-year and by 84% since the previous quarter
The company's quick ratio has shrunk by 89% YoY and by 84% QoQ
Royalty Pharma's debt is 26% lower than its equity
Royalty Pharma's debt has increased by 24% YoY
The debt to equity has increased by 16% YoY but it has decreased by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.